

Media release

Zug, 29 March 2018

Another successful IPO from HBM Healthcare Investments' portfolio: Homology Medicines raises USD 144 million

With Homology Medicines (Nasdaq: FIXX), another private company from the HBM Healthcare Investments portfolio went public yesterday. Due to the high demand, the company upsized its offering from 6.7 million to 9 million new shares. The shares were placed at a price of USD 16 per share, raising a total of USD 144 million in new capital for the company. On yesterday's first trading day, the share price rose to USD 18.66 (+16.6%).

HBM Healthcare Investments took an initial USD 4 million stake in Homology in July 2017 (purchase of 0.53 million shares at USD 7.58) and participated with an additional USD 6 million in the IPO. Following the IPO, HBM Healthcare Investments holds approximately 0.9 million shares worth USD 16.8 million. As a result of the IPO, the net asset value per HBM-share (NAV) increases by CHF 0.80 (+0.5%).

Homology advances a proprietary gene therapy and gene editing platform for the treatment of rare genetic diseases.

For further information, please contact Dr. Andreas Wicki, Tel. +41 41 710 75 77, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd.

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.